



HHS Public Access

Author manuscript

Autoimmune Infect Dis. Author manuscript; available in PMC 2016 August 22.

Published in final edited form as:

Autoimmune Infect Dis. 2016 June ; 2(3): .

Genetic Polymorphisms of TLR4 and MICA are Associated with Severity of Trachoma Disease in Tanzania

Muneer Abbas^{1,*}, Nouredine Berka², Mozna Khraiweh³, Ali Ramadan⁴, Victor Apprey^{1,5}, Paulette Furbert-Harris¹, Thomas Quinn⁶, Hassan Brim⁴, and Georgia Dunston¹

¹Department of Microbiology, Howard University, Washington, DC, USA

²Calgary Laboratory Services, Tissue Typing Laboratory, Canada

³Division of Experimental Therapeutics, Department of Drug Discovery, Walter Reed Army Institute of Research, Silver Spring, MD, USA

⁴Department of Pathology, Howard University Hospital, Washington, DC, USA

⁵Department of Community Health and Family Medicine, Howard University, Washington DC, USA

⁶International Health, School of Medicine, Johns Hopkins University, Baltimore Maryland, USA

Abstract

Aim—To examine the association of TLR4 Asp299Gly and MICA exon 5 microsatellites polymorphisms with severity of trachoma in a sub-Saharan East Africa population of Tanzanian villagers.

Methods—The samples were genotyped for MICA exon 5 microsatellites and the TLR4 299 A/G polymorphism by Restriction Fragment Length Polymorphism (RFLP), and GeneScan[®], respectively. The association of TLR4 Asp299Gly and MICA exon 5 microsatellites with inflammatory trachoma (TI) and trichiasis (TI) were examined.

Results—The results showed an association between TLR4 and MICA polymorphisms and trachoma disease severity, as well as with protection. TLR4 an allele was significantly associated with inflammatory trachoma ($p=0.0410$), while the G allele ($p=0.0410$) was associated with protection.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Muneer Abbas, Assistant Professor, Department of Microbiology, Howard University, Washington, DC, USA, Tel: +1-202-806-9437, Fax: +1-202-986-3972, m_abbas@howard.edu.

Author Contributions: MA: Wrote the paper and performed the assays.

MK, AR, VA, PF-H, HB had analyzed the data.

GD, NB, TQ had designed the research.

Institutional Review Board Statement: The study was approved by the institutional review board at Johns Hopkins University.

Informed Consent Statement: Informed consent was obtained for immunogenetic studies in 1996 in accordance with the Declaration of Helsinki.

Conflict of Interest: Nothing to disclose

Conclusion—TLR4 and MICA may modulate the risk of severity to trachoma disease by modulating the immune response to *Ct*. In addition; the increased frequency of MICA-A9 heterozygote in controls may suggest a positive selection of these alleles in adaptation to environments where *Ct* is endemic.

Keywords

Trachoma; *Chlamydia trachomatis*; Inflammation; Trichiasis; Single nucleotide polymorphism; Toll like receptor 4; Microsatellite polymorphism; Major histocompatibility complex (MHC) class I chain related gene A; MICA

Core Tip

Genetic polymorphisms in Toll like receptor 4 (TLR4) and Major histocompatibility complex (MHC) class I chain related gene (MICA) might be associated with host immunity to Trachoma disease and its subclinical phenotypes. Since their alleles vary among individuals and may confer variable disease susceptibilities, understanding the significant role that MICA and TLR4 alleles play in host inflammatory response is useful in research studies on inflammatory diseases. The data suggest that Tanzanians who carry the MICA-A9 and Asp299Gly TLR4 G alleles have lower risk to Trachoma disease.

Introduction

Trachoma disease is characterized by repeated episodes of Gramnegative *Chlamydia trachomatis* (*Ct*) infections. The infection causes a chronic inflammatory and immune fibrogenic process leading to conjunctival scarring and blinding sequel [1]. Approximately, 84 million individuals worldwide have active infections; 1.2 million are estimated to have visual impairment, and 3% to have blindness [2,3]. The ocular disease progresses through five stages, which may overlap with increasing severity. These phases include trachomatous inflammation, follicular (TF), trachomatous inflammation, intense (TI), trachomatous scarring (TS), trachomatous trichiasis (TT), and corneal opacity (CO). According to this classification, the first two grades TF and TI represent acute infection, whereas the other three grades represent the chronic stage of the disease [4,5].

Prolonged inflammation may lead to TS and TT. Although many individuals are infected with *Ct*, only 3% will develop blinding sequel. Moreover, the majority of infections are asymptomatic and evidence has shown that disease might persist weeks after the infection has resolved itself [6]. This may indicate that host genetic factors might play an important role in modulating the inflammatory response to *Ct*, thereby determining the pathogenesis of Trachoma diseases. Candidate genes underlying the immune response to bacterial infection are ideal targets for studying their genetic polymorphisms and their association with *Ct* pathogenesis.

Major histocompatibility complex (MHC) class I chain related gene A (MICA) plays an important role as ligand for activating killer cell C-type lectin-like receptors, subfamily D (NKG2D) (natural-killer group 2, member D) receptors expressed on the surface of all CD8 $\alpha\beta$ T cells, $\gamma\delta$ T cells, and most NK cells [7]. Under normal conditions, expression of MICA

molecules is restricted to intestinal and thymic epithelium [8]. When MICA is engaged by activating NKG2D, the latter functions as a signal transducer of cellular distress and triggers a range of immune effectors mechanisms including cellular cytotoxicity, cytokine secretion, and cellular proliferation [9]. There are 101 recognized human MICA alleles and 41 different MICB alleles that have been identified so far by the European Bioinformatics Institute [10,11]. The microsatellite polymorphism in exon 5 of the MICA gene consists of eight alleles based on the number of GCT/AGC triplet repeat units (alleles A4, A5, A6, A7, A8, A9, A10) and the presence of an additional nucleotide G/C insertion (allele A5.1) [12-14]. Microsatellite polymorphisms of the MICA have been shown to be associated with immunologically-mediated diseases such as the chronic systemic inflammatory disorder Behcet's disease [15].

Toll-like receptor 4 (TLR4) is a pattern recognition receptor for lipopolysaccharide (LPS) [16,17] and has been shown to induce the expression of genes involved in inflammatory responses [18,19]. Upon infection with *Ct*, the bacterial LPS is bound by LPS binding protein (LBP) and transferred to a receptor complex consisting of CD14, TLR4, and the adapter molecule MD2. This complex will initiate a signal transduction cascade leading to the release of pro-inflammatory cytokines such as tumor necrosis factor α (TNF- α) via the transcription factor nuclear factor (NF κ B) [20]. Several single nucleotide polymorphisms (SNPs) in TLR4 have been reported to modulate the responsiveness to LPS by lowering the affinity to LPS [21]. Epithelial cells respond to *Ct* LPS with the nuclear translocation of NF- κ B, indicating that signaling occurs through interaction with TLR4 and CD14, leading to the release of pro-inflammatory cytokines [22]. Twenty-nine SNPs have been identified in the human TLR4 gene [23]. Of these, the Asp299Gly (rs4986790) polymorphism has been shown to cause hyporesponsiveness to LPS in human alveolar macrophages and airway epithelial cell [24]. Individuals carrying the Asp299Gly TLR4 allele have lower levels of proinflammatory cytokines, acute-phase reactants, and soluble adhesion molecules, such as interleukin 6 and fibrinogen [25].

Given that inflammation and innate immunity are strongly implicated in the pathogenesis of trachoma infection, and that genetic variations in TLR4 and MICA affect the innate immune response, the aim of this study was to determine whether the TLR4 Asp299Gly and MICA microsatellite polymorphisms contribute to the susceptibility and severity of Trachoma disease in a Tanzanian population.

Materials and Methods

Informed consent was obtained for immunogenetic studies in 1996 in accordance with the Declaration of Helsinki and was approved by the institutional review board at Johns Hopkins University. The samples in this study were collected under a Johns Hopkins University approved IRB protocol for immunogenic studies in patients with Trachoma from Tanzania. We previously published first set of data from these samples [26]. All adult recruited patients gave a written consent form, while minors had their parents or guardians signed on their behalf.

Study participants

Two subject groups were included in this study. The first was the Trichiasis Study Group (TSG), whose subjects were culled from a longitudinal study started in 1989 on the development of scarring and trichiasis in women ($n=4932$) [27]. In 1996, a subset of 186 infected and 186 uninfected women were randomly chosen from a population-based sample of women and girls aged 16 and older from 11 villages in Kongwa district, Dodoma region, Tanzania [28]. At follow-up in 1999, 74 subjects were infected and 85 were uninfected; 73% of the subjects were infected in both 1996 and 1999 with the same *chlamydia ompA* genovar. Those who had chronic infection were more likely to have had trichiasis, scarring, and active trachoma in 1996 [28,29]. Overall, there were 127 samples, and DNA was suitable for analysis in 122. Cases were women and girls with trichiasis \pm inflammatory trachoma (TI) ($n=21$), and controls were women and girls with no or minimal disease (nonscarring, noninflammatory follicular trachoma, with or without infection [$n=77$]).

In the second group, the Family Trachoma Study (FTS), 15 families from one village were chosen because they had persistently infected children (probands) at three time points in a 1-year period ($n=15$). *OmpA* genotyping data indicated that this was likely persistent infection or reinfection with the same strain [30], suggesting an inability to mount a protective response. These children constituted the cases. The controls were meant to be their parents ($n=12$) and siblings ($n=40$) who had minimal or no disease (i.e., two parents had follicles, but no control had inflammation, scarring, or trichiasis).

Disease was classified using the simplified World Health Organization clinical grading scheme of the tarsal conjunctiva as follows: no trachoma (TN), 5 follicles of at least 0.5 mm each as follicular trachoma (TF), 50% of normal deep tarsal vessels obscured because of inflammatory thickening of upper tarsal conjunctiva as inflammatory trachoma (TI \pm TF), and at least 1 eyelash touching the cornea or evidence of recent removal of in-turned lashes as trichiasis (TT) [31].

Chlamydial DNA

A previously published and validated polymerase chain reaction-enzyme immunoassay for a conserved region of the MOMP-1 gene was used to detect *C. trachomatis* infection from lysed tarsal conjunctival swabs [32]. This study also describes the collection and processing of ocular samples. Every fifth PCR sample consisted of a swab inserted into PCR buffer by the sampler in the field. The contamination rate was 0.1%.

DNA extraction

DNA was extracted as described in a previous publication [26]. DNA samples from buccal mucosa were obtained in 1999 in the field, using sterile nylon cytology brushes (Medical Packaging Corp, Camarillo CA). This method was used because peripheral blood mononuclear cells were difficult to obtain at the time, and this method has been shown to be suitable for different genetic analysis methods. The brush was gently twirled on the buccal surface, and then placed into separate envelopes and stapled to the participant's data sheet and consent form. Samples were dried in the porous envelope, which aided in the preservation of the DNA. The cytology brushes were placed in 0.6 ml of 50 mM NaOH and

0.2 mM EDTA, followed by incubation at 80°C for 10 minutes, and cooling to 25°C. The brushes were then gently agitated and removed to release DNA. The samples were neutralized with 50 µl of 1 M Tris-Cl. For longer storage, an equal volume of 90% glycerol/water was added to the lysate and preserved at -80°C.

In order to eliminate any suspended proteins and RNAs, all DNA samples were further purified using QIAamp (Qiagen Inc., Valencia CA). Briefly, 400 µl of the preserved lysate were placed in a 2 ml microcentrifuge tube containing 20 µl of Proteinase K. The tubes were then incubated at 56°C for 10 min, followed by the addition of 400 µl of ethanol (96–100%) to the samples. 700 µl of the mixture from the previous step was applied to the QIAamp Spin Column and was centrifuge at 6000 × g (8000 rpm) for 1 min. The QIAamp Spin Column was placed in a clean 2 ml collection tube and the filtrate was safely discarded. After repeating the centrifugation step, 500 µl of AW1 Buffer was added to the spin column and centrifugation was performed at 6000 × g (8000 rpm) for 1 min. This step was repeated with AW2 buffer. In the last step QIAamp Spin Column was placed in a clean 1.5 ml microcentrifuge tube to which 150 µl of AE Buffer was added followed by incubation at room temperature for 1 min, and then centrifuged at 6000 × g (8000 rpm) for 1 min. The purified DNA was stored at -20°C.

Restriction fragment length polymorphism (RFLP)

TLR4Asp299Gly polymorphism was selected by designing primers from regions flanking the polymorphic site and distinguishing the normal and mutant alleles by size on agarose gels. The procedure was performed according to Lorenz et al. [33]. The forward primer sequence was altered to generate a restriction site in the minor allele. The following primer pair was used for TLR4 Asp299Gly, forward 5'-GATTAGCATACTTAGACT ACTACCTCCATG-3' and reverse 5'-GATCAACTTCTGAAAAAGCATCCCCAC-3'. The underlined bases in forward primer indicate the nucleotide altered to create *NcoI* (TLR4Asp299Gly) restriction site. Reactions were performed using the Platinum Taq[®] PCR kit (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) was performed in a total volume of 33 µl (20 to 60 ng of genomic DNA, 0.5 U *Taq* DNA polymerase, 10 pmol of each primer, 10 mmol of each dNTP, and 50 mmol MgCl₂). Reactions were run on a 96-Well GeneAmp[®] PCR System 9700 (Applied Biosystems, Foster City, CA USA) using the following conditions: 94°C for 1 min, then 30 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s). Eight microliters of the resulting PCR products were used for an overnight digest with restriction enzyme, and analyzed using 4% agarose gel electrophoresis system (BMA, Rockland, ME, USA) to determine the TLR4 allele.

Microsatellite for MICA

For analysis of microsatellite repeat polymorphism in the TM region of the MICA gene, the following primers were described before [34]: forward MICA5: 5'-CTTTTTTTCAGGGAAAGTGC-3' and reverse MICA5R: 5'-CCTTACCATCTC-CAGAAACTGC-3'. The forward primer was labeled at the 5' end with 6-FAM (PE Biosystems, Foster City, CA). PCR reactions were carried out using the Ampli-Taq Gold[®] PCR kit (Applied Biosystems, Foster City, CA, USA). PCR was performed in a total volume

of 25 μ L (5 μ l of 20 to 60 ng of genomic DNA, 0.5 U Taq DNA polymerase, 10 pmol of each primer, 10 mmol of each dNTP, and 25 mmol $MgCl_2$). Reactions were loaded on a 96-Well GeneAmp[®] PCR System 9700 (Applied Biosystems, Foster City, CA USA) using the following conditions: 94°C for 2 min, then 30 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min. To determine the number of triplet repeats in the TM region of the MICA gene, 1 μ l of the pooled PCR products was mixed with 10 μ l of formamide and denatured for 5 min at 95°C. The samples were then placed on ice for at least 5 min, after which they were loaded onto an ABI PRISM 3100 (Applied Biosystems, Foster City, CA USA). The data generated from ABI 3100 were analyzed using the GeneScan[®] Analysis Software. Its algorithms automatically identify and size each peak relative to an internal size standard, as well as provide peak area and peak height information. The results from Gene Scan software were imported and filtered using Genotyper[®] software to provide final results such as allele calls and automated table building.

Statistical analysis

The statistical analyses were performed using the SAS/STAT[®] software, version 9.1 (SAS Institute Inc., Cary, NC). Differences in subject characteristics were compared by the chi-square or Fisher's exact test for categorical values or by Student's t-test for continuous variables. Hardy Weinberg Equilibrium (HWE) was calculated using control subjects by comparing expected genotype frequencies to observed genotype frequencies using chi-square. For each SNP genotype, tests using the codominant, dominant, recessive, and log-additive genetic models were performed. Unconditional logistic regression models were used to calculate odds ratios (ORs) with 95% confidence intervals for genotypes in order to estimate the effect of the SNP presence on Trachoma risk controlling for age. Two-sided p-values ≤ 0.05 were considered as statistically significant. Participants with missing values were omitted from the analyses. Genetic modeling was performed using the statistical analysis package R (Lucent Technologies, Murray Hill, NJ).

Results

The MICA-A9 allele was found to be statistically significant in both TI (OR=0.63 95% CI: 0.4164-0.9532, $p=0.0520$) and TT (OR=0.53 95% CI: 0.3306-0.8496, $p=0.0239$) groups when compared to the control group (TN) (Table 1).

When the MICA-A9 genotypic frequency distribution was measured against the rest of the MIC-A alleles, we found that it was significantly associated with developing trichiasis (TT) when compared to the controls (OR=2.324 95% CI: 1.187-4.548, $p=0.016$; Table 2). Also, the relative risk is increased in subjects who are heterozygosity and homozygous for the MICA-A9. The results showed that the risk was three times higher when the MICA A9 allele was absent in the TT patients (OR=1.549 95% CI: 1.104-2.017, $p=0.016$; (Table 2) which indicates a protective role in the population.

The TLR4 A allele frequency was significantly higher in inflammatory trachoma cases (OR=6.350, 95% CI: 1.167-34.538, $p=0.0410$) while the TLR G allele was higher in the controls (OR=0.160 95% CI: 0.029-0.870, $p=0.0410$; Table 3). Allele and genotype frequencies did not differ significantly between TT patients and healthy controls, while in

the TI group TLR4 A/A was significantly higher in the cases and the heterozygosity was higher in the controls (Table 4).

Discussion

The data presented here show that genomic variation in the human MICA microsatellite in exon 5 and in TLR4 Asp299Gly are associated with the conjunctival inflammatory response due to the infection with the human pathogen *Ct*. pathogenic environment is a major determinant of the evolutionary pathway that leads to the change in the genetic makeup of the innate immune system genes. Polymorphisms in TLR4 and MICA are examples of these changes and have been related to the biology of the inflammatory responses to bacterial infections [35,36]. MICA interacts with NKG2D activating receptor expressed on CD8+ T cells, gamma delta T cells, and NK cells in humans [7]. MICA is known to trigger NK cells and co-stimulates some $\gamma\delta$ T cells and antigen-specific $\alpha\beta$ CD8+ T cells by engaging NKG2D expressed on these cells. In $\alpha\beta$ CD8 T cells, NKG2D/MIC engagement delivers a co-stimulatory signal that complements TCR-mediated antigen recognition on target cells. Allez et al. [37] provided evidence that MICA expression was significantly increased on intestinal epithelial cells isolated from patients with crohn's disease and inflammatory bowel disease, which indicates the role of MICA in the inflammatory response of stressed epithelial cells. Mei et al. [38] investigated the association of polymorphic extracellular domains of MICA alleles with genital *Ct* that cause tubal infertility in women. The data suggested that the MICA locus might modify host inflammatory response to *Ct* infection. In this study, MIC-A9 allele was found to be more frequent in the healthy subjects, which indicates a protective role. Mok et al. [39] reported on a possible protective role of MICA-A9 in the susceptibility to rheumatoid Arthritis in Korean subjects. Also, It has previously been reported that the MICA-A9 allele might confer protection from IDDM and celiac disease in the Spanish population [40,41]. This indicates that cells expressing MICA-A9 molecules might be properly recognized by $\gamma\delta$ T cells, CD8+ $\alpha\beta$ T and NK cells, all of which are likely to have a role in overcoming Chlamydial infection and subsequently resolving Trachoma disease.

The noticeable degree of association of polymorphism that encodes structural modifications to the extracellular domain of TLR4 [24,42] with bacterial infections in different populations [43-45] provides compelling evidence for a role for this key innate immune signaling molecule in the response to Gram-negative bacterial infections. In our study, the TLR4 G allele was found to be protective ($p=0.0410$) and the A allele to have a predisposing in the TI phenotypes ($p=0.0404$ and 0.0410 respectively). Predictive modeling studies [24,46] indicate that this SNP is situated in the binding domain of the TLR4 protein and that inheritance of the SNP would interpose conformational changes that could potentially alter interaction of TLR4 with other molecules such as MD2 that is required for signaling. The TLR4 A/G genotype was found to be protective in the inflammatory trachoma when compared to the A/A homozygous genotype. Similar results were noticed in this study for MICA-A9 heterozygote that was relatively high in the Tanzanian population, and the risk increased as the MICA-A9 genotypes for heterozygote and homozygotes rates decreased in the healthy controls. The theory of heterozygote advantage [47] is often used to explain the genetic variation found in natural populations which might explain the protective role of MICA-A9

heterozygosity. Our results indicate that MICA-A9 and TLR4 Asp299Gly heterozygosity may confer a selective advantage in Tanzanian populations where Trachoma is endemic.

In summary, our findings suggest that MICA and TLR4 may associate with host immunity to Trachoma disease and its subclinical phenotypes. Since their alleles vary among individuals and may confer variable disease susceptibilities, understanding the significant role that MICA and TLR4 alleles play in host inflammatory response is useful in research studies on inflammatory diseases. Our results demonstrate that Tanzanians who carry the MICA-A9 and Asp299Gly TLR4 G alleles have lower risk to Trachoma disease. Further investigation can focus on the structure function relationship of these polymorphisms to mechanism of activity in regulation of the inflammatory response to *Ct* infections in Trachoma.

Acknowledgments

The authors thank Harran Mkocho and the Kongwa Trachoma Project for the field component and Virginia Turner and Sidney Katala for assembling the original Trichiasis in Women cohort and also many thanks to Gaurav Tripathi and Abubaker Sidahmed for their comments on the manuscript.

Funded by: National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant RR03048; National Institutes of Health/National Center for Research Resources Grant 2G12RR003048; and the National Human Genome Center for the African Diaspora, Howard University, Washington, DC.

References

1. Last AR, Burr SE, Weiss HA, Harding-Esch EM, Cassama E, et al. Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naive trachoma-hyperendemic communities of the Bijagos Archipelago, Guinea Bissau. *PLoS negl Trop Dis.* 2014; 8:e2900. [PubMed: 24967629]
2. WHO. WHO Alliance for the Global Elimination of Blinding Trachoma by 2020. WHO Press; Geneva: 2006. 10th Meeting Of Get2020 Report. Making progress toward the global elimination of blinding trachoma.
3. WHO. Prevention of blindness and visual impairment. Priority eye diseases. 2016
4. Holland MJ, Bailey RL, Conway DJ, Culley F, Miranpuri G, et al. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. *Clin Exp Immunol.* 1996; 105:429–435. [PubMed: 8809130]
5. Taylor HR, Johnson SL, Schachter J, Caldwell HD, Prendergast RA. Pathogenesis of trachoma: the stimulus for inflammation. *J Immunol.* 1987; 138:3023–3027. [PubMed: 3571982]
6. Wright HR, Keeffe JE, Taylor HR. Trachoma and the need for a coordinated community-wide response: a case-based study. *PLoS medicine.* 2006; 3:e41. [PubMed: 16492074]
7. Bahram S. MIC genes: from genetics to biology. *Adv Immunol.* 2000; 76:1–60. [PubMed: 11079097]
8. Hüe S, Mention JJ, Monteiro RC, Zhang S, Cellier C, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. *Immunity.* 2004; 21:367–377. [PubMed: 15357948]
9. Vetter CS, Groh V, Straten P, Spies T, Brocker EB, et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. *J Invest Dermatol.* 2002; 118:600–605. [PubMed: 11918705]
10. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. *Nucleic Acids Res.* 2003; 31:311–314. [PubMed: 12520010]

11. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, et al. The IPD and IMGT/HLA database: allele variant databases. *Nucleic Acids Res.* 2015; 43:D423–D431. [PubMed: 25414341]
12. Fodil N, Laloux L, Wanner V, Pellet P, Hauptmann G, et al. Allelic repertoire of the human MHC class I MICA gene. *Immunogenetics.* 1996; 44:351–357. [PubMed: 8781120]
13. Gambelungho G, Brozzetti AL, Ghaderi M, Tortoioli C, Falorni A. MICA A8: a new allele within MHC class I chain-related A transmembrane region with eight GCT repeats. *Hum Immunol.* 2006; 67:1005–1007. [PubMed: 17174750]
14. Ji M, Wang J, Yuan L, Zhang Y, Zhang J, et al. MICA polymorphisms and cancer risk: a meta-analysis. *Int J Clin Exp Med.* 2015; 8:818–826. [PubMed: 25785062]
15. Park Y, Lee H, Sanjeevi CB, Eisenbarth GS. MICA polymorphism is associated with type 1 diabetes in the Korean population. *Diabetes Care.* 2001; 24:33–38. [PubMed: 11194237]
16. Takeda K, Akira S. Toll-like receptors in innate immunity. *Int Immunol.* 2005; 17:1–14. [PubMed: 15585605]
17. Blasius AL, Beutler B. Intracellular toll-like receptors. *Immunity.* 2010; 32:305–315. [PubMed: 20346772]
18. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. *Curr Opin Immunol.* 1997; 9:4–9. [PubMed: 9039775]
19. Sabroe I, Parker LC, Dower SK, Whyte MK. The role of TLR activation in inflammation. *J Pathol.* 2008; 214:126–135. [PubMed: 18161748]
20. Schroder NW, Meister D, Wolff V, Christan C, Kaner D, et al. Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 gene. *Genes Immun.* 2005; 6:448–451. [PubMed: 15875057]
21. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. *J Immunol.* 2001; 167:5838–5844. [PubMed: 11698458]
22. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, et al. The inflammatory cytokine response to *Chlamydia trachomatis* infection is endotoxin mediated. *Infect Immun.* 1995; 63:3125–3130. [PubMed: 7542638]
23. Raby BA, Klimecki WT, Laprise C, Renaud Y, Faith J, et al. Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. *Am J Respir Crit Care Med.* 2002; 166:1449–1456. [PubMed: 12406828]
24. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet.* 2000; 25:187–191. [PubMed: 10835634]
25. Kim YS, Hwang YJ, Kim SY, Yang SM, Lee KY, et al. Rarity of TLR4 Asp299Gly and Thr399Ile Polymorphisms in the Korean Population. *Yonsei Med J.* 2008; 49:58–62. [PubMed: 18306470]
26. Abbas M, Bobo LD, Hsieh YH, Berka N, Dunston G, et al. Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers. *Invest Ophthalmol Vis Sci.* 2009; 50:1734–1738. [PubMed: 18824733]
27. Turner VM, West SK, Munoz B, Katala SJ, Taylor HR, et al. Risk factors for trichiasis in women in Kongwa, Tanzania: a case-control study. *International journal of epidemiology.* 1993; 22:341–347. [PubMed: 8505194]
28. Munoz B, Bobo L, Mkocho H, Lynch M, Hsieh YH, et al. Incidence of trichiasis in a cohort of women with and without scarring. *International journal of epidemiology.* 1999; 28:1167–1171. [PubMed: 10661664]
29. Smith A, Munoz B, Hsieh YH, Bobo L, Mkocho H, et al. OmpA genotypic evidence for persistent ocular *Chlamydia trachomatis* infection in Tanzanian village women. *Ophthalmic epidemiol.* 2001; 8:127–135. [PubMed: 11471082]
30. Hsieh, YHWS.; Bobo, L.; Munoz, B.; Quinn, TC. The 39th Annual Meeting of the Infectious Diseases Society of America. California: 2001.
31. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. *Bull World Health Organ.* 1987; 65:477–483. [PubMed: 3500800]
32. Bobo L, Munoz B, Viscidi R, Quinn T, Mkocho H, et al. Diagnosis of *Chlamydia trachomatis* eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. *Lancet.* 1991; 338:847–850. [PubMed: 1681215]

33. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. *BioTechniques*. 2001; 31:22–24. [PubMed: 11464514]
34. Foissac A, Cambon-Thomsen A. Microsatellites in the HLA region: 1998 update. *Tissue Antigens*. 1998; 52:318–352. [PubMed: 9820597]
35. Hook CE, Telyatnikova N, Goodall JC, Braud VM, Carmichael AJ, et al. Effects of *Chlamydia trachomatis* infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis. *Clin Exp Immunol*. 2004; 138:54–60. [PubMed: 15373905]
36. Tieng V, Le Bouguenec C, du Merle L, Bertheau P, Desreumaux P, et al. Binding of *Escherichia coli* adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. *Proc Natl Acad Sci U S A*. 2002; 99:2977–2982. [PubMed: 11830641]
37. Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. *Gastroenterology*. 2007; 132:2346–2358. [PubMed: 17570210]
38. Mei B, Luo Q, Du K, Huo Z, Wang F, et al. Association of MICA gene polymorphisms with *Chlamydia trachomatis* infection and related tubal pathology in infertile women. *Hum Reprod*. 2009; 24:3090–3095. [PubMed: 19783834]
39. Mok JW, Lee YJ, Kim JY, Lee EB, Song YW, et al. Association of MICA polymorphism with rheumatoid arthritis patients in Koreans. *Hum Immunol*. 2003; 64:1190–1194. [PubMed: 14630402]
40. Bilbao JR, Martin-Pagola A, Calvo B, Perez de Nanclares G, Gelpi N, et al. Contribution of MIC-A polymorphism to type 1 diabetes mellitus in Basques. *Ann N Y Acad Sci*. 2002; 958:321–324. [PubMed: 12021133]
41. Bilbao JR, Martin-Pagola A, Vitoria JC, Zubillaga P, Ortiz L, et al. HLA-DRB1 and MHC class I chain-related A haplotypes in Basque families with celiac disease. *Tissue Antigens*. 2002; 60:71–76. [PubMed: 12366785]
42. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, et al. Leucine-rich repeats and pathogen recognition in Toll-like receptors. *Trends Immunol*. 2003; 24:528–533. [PubMed: 14552836]
43. Trejo-de la OA, Torres J, Pérez-Rodríguez M, Camorlinga-Ponce M, Luna LF, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with *Helicobacter pylori*-associated gastroduodenal diseases. *Clin Immunol*. 2008; 129:333–340. [PubMed: 18755634]
44. Faber J, Meyer CU, Gemmer C, Russo A, Finn A, Murdoch C, et al. Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. *Pediatr Infect Dis J*. 2006; 25:80–81. [PubMed: 16395111]
45. Yuan FF, Marks K, Wong M, Watson S, de Leon E, et al. Clinical relevance of TLR2, TLR4, CD14 and FcγRIIA gene polymorphisms in *Streptococcus pneumoniae* infection. *Immunology and cell biology*. 2008; 86:268–270. [PubMed: 18180796]
46. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. *Biochem Soc Trans*. 2007; 35:1473–1478. [PubMed: 18031248]
47. Edwards JH. Heterozygote advantage. *Archives of disease in childhood*. 1977; 52:343–344. [PubMed: 869563]

Table 1
Association of MICA microsatellite alleles with TI and TT clinical phenotypes of Trachoma

Microsatellite allele	Cases	Controls	P-value	Odds Ratio [95% CI]
	TI			
	(104)	(348)		
A4	6	16	0.6261	1.27[0.5673-2.8431]
A5	7	10	0.0697	2.44[1.0657-5.5864]
A5.1	25	80	0.8239	1.06[0.6898-1.6289]
A6	40	121	0.4903	1.17[0.8018-1.7073]
A9	26	121	0.0520	0.63[0.4164-0.9532]
	TT			
	(82)	(370)		
A4	5	17	0.5672	1.35[0.5726-3.1830]
A5	5	12	0.2190	1.94[0.7926-4.7486]
A5.1	23	82	0.2534	1.37[0.8722-2.1519]
A6	31	130	0.6478	1.12[0.7410-1.6929]
A9	18	129	0.0239	0.53[0.3306-0.8496]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2
Genotypic frequencies for MICA- A9 microsattelite in the TI and TT clinical phenotypes of Trachoma

MICA-A9 Genotype	Cases(n)	Controls(n)		p-value	Odds Ratio [95% CI]	Relative risk[95% CI]
		TI				
	(52)	(174)				
9:9	4	23	23	0.399	0.547[0.189-1.595]	0.582[0.214-1.499]
9:x	18	75	75	0.336	0.699[0.369-1.325]	0.803[0.521-1.174]
x:x	30	76	76	0.083	1.758[0.944-3.273]	1.321[0.970-1.708]
		TT				
	(41)	(217)				
9:9	1	26	26	0.092	0.184[0.031-1.103]	0.204[0.035-1.091]
9:x	16	109	109	0.233	0.634[0.323-1.244]	0.777[0.502-1.115]
x:x	24	82	82	0.016	2.324[1.187-4.548]	1.549[1.104-2.017]

X: Allele other than A9. Significant p value (<0.05)

Table 3
Association of TLR4 Asp299Gly alleles with Trachoma in Tanzania

TLR4 allele	Cases (n)	Controls (n)	P-value	Odds Ratio[95% CI]
	TI			
	(118)	(330)		
A	113	313	0.0410	6.350[1.167-34.538]
G	5	17	0.0410	0.160[0.029-0.870]
	TT			
	(100)	(348)		
A	94	336	0.2521	0.560[0.242-1.298]
G	6	12	0.2521	1.790[0.772-4.148]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4
Association of TLR4 Asp299Gly genotypes with Trachoma in Tanzania

TLR4 Genotypes	Cases (n)	Controls (n)	p-value	Odds Ratio[95% CI]	Relative risk[95% CI]
	(59)	(165)			
A/A	58	149	0.0464	6.230[1.131-34.313]	1.000[0.735-1.361]
A/G	1	15	0.0583	0.170[0.031-0.939]	0.223[0.033-1.50]
G/G	0	1	-	-	-
A/A	44	163	0.1815	0.490[0.204-1.177]	1.000[0.691-1.448]
A/G	6	10	0.1303	2.240[0.920-5.453]	1.764[0.891-3.495]
G/G	0	1	-	-	-